Medical Angels, an Australian early stage healthtech fund founded by medical professionals, has appointed Michael Batko, founder of Hourglass AI, as a part-time venture partner to help raise and manage its $40 million fund, leveraging clinical expertise to back promising ventures.
- Michael Batko joins Medical Angels as venture partner to raise $40m fund.
- Fund backed by over 1,400 Australian doctors with $4m committed so far.
- Focus on clinical diligence to address healthtech capital and operational barriers.
What happened
Medical Angels, a healthtech venture fund started by Australian medical doctors, has transitioned into an Early Stage Venture Capital Limited Partnership with a target of raising $40 million. To drive this initiative, it appointed Michael Batko, founder of Hourglass AI and ex-Startmate boss, as a part-time venture partner. Batko’s role includes managing the fundraise, investor relations, and fund operations, while the network of more than 1,400 doctors continues to guide investment decisions based on clinical expertise.
The fund has quickly gained traction, securing $4 million in commitments within the first ten weeks. Medical Angels’ portfolio includes companies like Smileyscope, a VR-based digital therapeutic for procedural pain in children; Coviu, a telehealth platform with significant usage during COVID-19; and Clean Slate Clinic, the first fully virtual alcohol detox program in Australia. The fund emphasizes clinical validation and real-world impact as key investment criteria.
Why it matters
Australian healthtech startups have historically struggled to attract sufficient venture capital due to the complexity of clinical markets, specialist regulatory pathways, and a generalist investor base unfamiliar with medical product efficacy and adoption challenges. Medical Angels addresses these issues by leveraging a physician-led investment model, positioning doctors both as informed investors and credible validators of clinical innovation.
The participation of Michael Batko brings operational and fundraising expertise to complement the clinical insight of the fund’s doctor-investors. This strategic combination aims to create a venture fund that can more effectively scale promising healthtech ventures, reduce friction at the investment stage, and enhance overall fund performance by aligning capital with medical realities.
What to watch next
Monitor the progress of Medical Angels as it continues to build its $40 million fund and the further deployment of capital into early stage Australian healthtech startups. The success of the fundraise and the ability to attract high-quality deal flow driven by doctor-led clinical assessment will be key indicators of the model’s scalability and impact on the national health innovation ecosystem.
Additionally, Michael Batko’s dual focus on his startup Hourglass AI and the fund’s operations will be a balancing act to watch, especially given AI’s rapid penetration into clinical environments. The fund’s capacity to identify safe, effective, and regulatory-compliant AI health solutions approved by its investor doctors could become a significant advantage amid evolving digital health landscapes.